Ana Pilar González

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Laura Rosiñol, Albert Oriol, Rafael Ríos et al. · Blood · 2019 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

Ramón García‐Sánz, Anna Sureda, Fátima De la Cruz et al. · Annals of Oncology · 2019 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González et al. · Cancers · 2021 · 100 citations · Full text

Life Sciences, Immunology, Immuno-oncology Pharmacotherapy +16

Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia

Ana Pilar González, Juan Contesti, Leticía Huergo-Zapico et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2010 · 92 citations · Full text

Medicine, Hematology, Oncology +14

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease

Leticía Huergo-Zapico, Andrea Acebes‐Huerta, Ana Pilar González et al. · PLoS ONE · 2014 · 82 citations · Full text

Life Sciences, Hematology, Immunology +16